Imaging Biometrics publishes 2025 annual report

  • Imaging Biometrics annual report for year ended Dec. 31, 2025 outlined strategic reset toward core imaging software, citing cost cuts intended to reduce cash burn and support scaling in 2026.
  • Kirkstall was fully acquired on Oct. 14, 2025, bringing Quasi Vivo organ-on-a-chip platform into group as second operating business.
  • Phase 1 clinical trial of oral gallium maltolate met objectives and completed; resources redirected away from further development pending funding.
  • Next-generation IB Nimble and enhanced IB Clinic platforms moved toward commercial release, with full PACS connectivity targeted by end of Q2 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Imaging Biometrics Ltd. published the original content used to generate this news brief on May 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.